fda approves first oral glp-1 obesity drug august 1 2025 FDA Approves Oral Semaglutide as

This result is square in the middle of that range AND Eli Lilly cautioned a few months ago that these results will not show the true efficacy or final weight loss potential. So, uh

[DOI] [PubMed] [Google Scholar] 71.Ma B, Wang X, Ren H, Li Y, Zhang H, Yang M, et al

Additional factors such as increased release of adiponectin from adipose tissue, amelioration of insulin resistance in liver and peripheral tissues, and improved circulatory lipid profile all contribute to the reduced risk of ASCVD (267)

While this study doesnt specifically look at eating disorders, it does suggest that people with eating disorders may be more likely to seek out GLP-1 medications

Studies have shown that retatrutide, when used as an add-on therapy to existing diabetes medications, significantly reduces HbA1c levelsa key marker of long-term blood sugar control

Reach out to us at The Hetrick Center to ask questions, build a plan, and see whether the supplement-first or supplement-adjunct path makes sense for you